# High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

> **NCT03870529** · EARLY_PHASE1 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 20 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Stage I Lung Cancer
- Stage Ib Lung Carcinoma
- Stage IA Lung Carcinoma AJCC V7
- Stage IIA Lung Carcinoma
- Stage IIIA Lung Carcinoma

## Interventions

- **DRUG:** Vitamin A Compound
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT03870529
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-19
- **Primary completion:** 2022-12-09
- **Final completion:** 2022-12-09
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Slow accruals
- **Last updated:** 2024-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03870529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03870529, "High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03870529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*